245 related articles for article (PubMed ID: 32505517)
21. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders.
Peschel C; Aulitzky WE; Huber C
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():129-34. PubMed ID: 8951783
[TBL] [Abstract][Full Text] [Related]
22. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
Fleischman AG
Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms.
Vukotić M; Kapor S; Dragojević T; Đikić D; Mitrović Ajtić O; Diklić M; Subotički T; Živković E; Beleslin Čokić B; Vojvodić A; Santibáñez JF; Gotić M; Čokić VP
Exp Mol Med; 2022 Mar; 54(3):273-284. PubMed ID: 35288649
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of chronic myeloproliferative syndromes using the technics of in vitro hematopoiesis (the origin and function of marrow stromal cells in CML)].
Takahashi M; Fujiwara M
Rinsho Ketsueki; 1988 Jul; 29(7):994-1000. PubMed ID: 3184486
[No Abstract] [Full Text] [Related]
25. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
26. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
[TBL] [Abstract][Full Text] [Related]
27. Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.
Mendez Luque LF; Blackmon AL; Ramanathan G; Fleischman AG
Curr Hematol Malig Rep; 2019 Jun; 14(3):145-153. PubMed ID: 31119475
[TBL] [Abstract][Full Text] [Related]
28. Relative fitness of hematopoietic progenitors influences leukemia progression.
Porter CC; Baturin D; Choudhary R; DeGregori J
Leukemia; 2011 May; 25(5):891-5. PubMed ID: 21331070
[No Abstract] [Full Text] [Related]
29. Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms.
Chen P; Wu B; Ji L; Zhan Y; Li F; Cheng L; Cao J; Chen H; Ke Y; Min Z; Sun L; Hua F; Chen H; Cheng Y
Front Med (Lausanne); 2021; 8():598182. PubMed ID: 34249954
[No Abstract] [Full Text] [Related]
30. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
Zhang J; Fleischman AG; Wodarz D; Komarova NL
J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
[TBL] [Abstract][Full Text] [Related]
31. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
32. [Heterogeneity of leukemia cell phenotype. I. Variants of hetero- phenotype in relation to myeloid and erythrocytic markers of leukemic cells in acute leukemia and blast crisis of chronic myeloproliferative disorders].
Kemnitz J; Helmke M; Frend M; Bür T; Dominis M; Horitz H
Gematol Transfuziol; 1990 Aug; 35(8):9-14. PubMed ID: 2253865
[No Abstract] [Full Text] [Related]
33. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.
Ikeda K; Ogawa K; Takeishi Y
Fukushima J Med Sci; 2012; 58(2):91-100. PubMed ID: 23237864
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
[TBL] [Abstract][Full Text] [Related]
35. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
36. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
37. Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver.
Bonometti A; Borsani O; Rumi E; Ferretti VV; Dioli C; Lucato E; Paulli M; Boveri E
Cancer Med; 2023 Apr; 12(7):7815-7822. PubMed ID: 36524315
[TBL] [Abstract][Full Text] [Related]
38. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
